Safety risks of interstitial lung disease upon real-world usage of Janus kinase inhibitors and biologics for patients with autoimmune diseases: epidemiological study using nationwide electronic medical record database in Japan-Reference-Cited by-同舟云学术

Safety risks of interstitial lung disease upon real-world usage of Janus kinase inhibitors and biologics for patients with autoimmune diseases: epidemiological study using nationwide electronic medical record database in Japan

Published:2024-02-21 Issue:3 Volume:47 Page:130-141
ISSN:2578-5826
Container-title:Immunological Medicine
language:en
Short-container-title:Immunological Medicine

Author:

Yabuuchi Mihoko¹²^ORCID,Yokoyama Kazuhito¹³^ORCID

Affiliation:

1. Department of Epidemiology and Environmental Health, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan

2. Medical Writing, Portfolio and Project Management, Pfizer R&D Japan G.K., Shibuya-ku, Tokyo, Japan

3. Department of Epidemiology and Social Medicine, International University of Health and Welfare Graduate School of Public Health, Minato-ku, Tokyo, Japan

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/25785826.2024.2311763

Reference50 articles.

1. Mitsubishi Tanabe Pharma Corporation. Japanese interview form of infliximab (REMICADE for I.V. infusion 100); 2022 [cited 2023 Jul 6]. Available from: https://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/2399402

2. Anti-cytokine therapy in collagen disease and rheumatology –update–: anti-cytokine therapy in allergy and autoimmunity;Tanaka Y.;J Japan Intern Med,2019

3. Pfizer. Japanese interview form of tofacitinib (XELJANZ Tablets 5 mg); 2023 [cited 2023 Jul 6]. Available from: https://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/3999034

4. Pfizer. Japanese risk management plan of tofacitinib (XEJJANZ Tablets 5 mg); 2023 [cited 2023 Jul 6]. Available from: https://www.pmda.go.jp/safety/info-services/drugs/items-information/rmp/0001.html

5. Eli Lilly and Company. Japanese risk management plan of baricitinib (Olminant tablets 4 mg/2 mg); 2023 [cited 2023 Jul 6]. Available from: https://www.pmda.go.jp/safety/info-services/drugs/items-information/rmp/0001.html